A Spotlight on Siolta Therapeutics

When asked about advice for other founders, Nikole Kimes offers wisdom that clearly comes from experience: “Listen to your gut. Many of us are not following a map. We are creating one. We are pushing into territory where precedent is scarce and certainty is rare. Trust your instincts. Your perspective is not a weakness; it is your edge.”

This philosophy has defined Siolta Therapeutics from the start. When Nikole co-founded the company, the vision was to prevent allergic diseases in infants before symptoms ever appear — not to manage them or treat them after diagnosis, but to stop them from developing in the first place.

In a recent conversation I had with CEO Nikole Kimes and CSO Ricardo Valladares, they shared the story behind Siolta’s approach to allergic disease prevention.

In November, Siolta Therapeutics announced positive Phase 2 results from their ADORED study, showing that their lead candidate, STMC-103H, significantly reduces the development of atopic dermatitis and food allergy in at-risk infants. The trial enrolled 238 newborns across 30 sites in the U.S. and Australia, with infants receiving daily doses of the live biotherapeutic throughout their first year of life.

The results represent a fundamental shift in how medicine approaches chronic inflammatory disease. Rather than suppressing symptoms after disease has already developed, Siolta’s approach focuses on early-life prevention — intervening during the critical first year of life, when the gut microbiome and immune system mature together and establish long-term inflammatory and immune responses.

“We were told early on that a prevention trial in newborns was going to be difficult, and some said we were crazy to try,” Nikole reflects. “With the recent positive topline safety and efficacy outcomes from the ADORED trial, we feel more confident than ever that we are on the right track.”

The Science Behind the Story

The company spun out of Dr. Susan Lynch’s lab at UCSF, where research revealed a striking pattern: children who develop allergic diseases lack certain beneficial bacteria in their gut during the first months of life. Similar findings were emerging from research groups worldwide, but what made the work especially compelling was the mechanistic evidence showing that restoring these specific missing bacteria in preclinical models could actively promote immune tolerance.

Dr. Lynch, Director of the Benioff Center for Microbiome Medicine and an internationally recognized leader in microbiome science, co-founded Siolta with Dr. Kimes and backing from Samir Kaul at Khosla Ventures. The founding team came together somewhat serendipitously — Kaul’s personal experience with allergic disease led him to Lynch’s research, and he encouraged her to translate her academic work into a product to help families suffering from conditions like asthma.

Ricardo Valladares, a former postdoc in the Lynch lab, joined as Chief Scientific Officer, bringing deep expertise in microbiology and microbial ecology. Together, the leadership team has built something remarkable: a clinical-stage pipeline advanced by a lean team of approximately 10 people, with impressive capital efficiency.

“From the start, the science suggested that early intervention with a microbial mixture could potentially prevent the underlying immune cascade that causes multiple atopic diseases,” Ricardo explains. But it challenged traditional drug-development approaches on multiple levels, which meant “a high bar for the level of data and stage of development required to advance such an idea.”

Beyond Traditional Medicine

What Siolta is developing isn’t a typical pharmaceutical. STMC-103H contains precisely formulated communities of beneficial bacteria — novel strains isolated and characterized in their lab with no prior human use history. These aren’t over-the-counter probiotics. They’re FDA-regulated live biotherapeutic products evaluated under the same rigorous standards for safety and efficacy as other biologics. Ricardo emphasizes that “given the safety concerns that have emerged around some consumer probiotics in recent years, we believe this rigorous path is essential, and ultimately the right one to bring safe and effective therapeutic options to patients.”

The company’s work addresses a pressing problem: rates of allergic diseases, including atopic dermatitis, food allergies, and asthma, have risen steadily over recent decades. Today, more than 1 in 4 U.S. children are affected. Despite substantial scientific progress, there are still no effective ways to prevent these conditions from developing. Families navigate complex care routines, heightened vigilance to avoid triggers, and frequent medical visits, making the emotional and financial burdens even more significant. But allergic disease is just the beginning.

Siolta’s microbiome approach extends beyond allergic disease prevention. This year, the company was awarded a $1.8 million Phase II SBIR to develop a live biotherapeutic for recurrent bacterial vaginosis, the most common vaginal infection affecting adult women. They’re also working on programs aimed at preventing necrotizing enterocolitis, a devastating intestinal disease in preterm infants.

Across each indication, disruption of the protective microbiome is a central driver of disease. The team’s approach is rooted in the belief that the right combination of beneficial microbes can restore balance and deliver meaningful preventive and therapeutic benefits to patients.

The Work Continues

Siolta has navigated challenges that would have stopped many companies: enrolling a prevention trial during the COVID-19 pandemic, developing a novel modality in an infant population, building manufacturing processes for historically difficult-to-culture bacteria, and navigating regulatory frameworks for an emerging therapeutic class. With two-year durability data readouts expected early next year, they’re on the verge of offering families the first evidence-based way to prevent allergic disease in their children.

Executed by a team that has demonstrated exceptional resourcefulness at every turn, Siolta Therapeutics is showing what’s possible when scientific rigor meets unwavering commitment to patient impact.

As Dr. Kimes might say, sometimes the most important paths are the ones you create yourself.

Learn more about Siolta Therapeutics here —>